NASDAQ · Biotechnology

IMRX (IMRX) Stock

$4.24 -2.75% NASDAQ: IMRX Healthcare

Valuation

MetricValue
Price$4.24
Market Cap$153.92M
P/E Ratio-3.94
P/B Ratio0.83
P/S Ratio0.00
EPS (TTM)$-1.27
52-Week High$10.08
52-Week Low$2.29
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-25.69%
ROA-24.14%
ROCE-27.06%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio17.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$0$0$0$0
Operating Profit$-34.0M$-52.0M$-58.0M$-64.0M$-59.0M
Net Profit$-34.0M$-51.0M$-53.0M$-61.0M$-56.0M
EPS$-1.27$-1.87$-1.88$-2.04$-1.27
Op Margin-1629.2%-16325.8%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$167.0M$122.0M$103.0M$53.0M$232.0M
Total Liabilities$11.0M$13.0M$12.0M$11.0M$14.0M
Cash$75.0M$73.0M$59.0M$36.0M$129.0M
Borrowings$5.0M$5.0M$4.0M$4.0M$4.0M

Latest News

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know Zacks · Jul 15, 2026 Immuneering Names Andrew Gengos as CFO MT Newswires · Jun 15, 2026 Immuneering Appoints Andrew Gengos as Chief Financial Officer GlobeNewswire · Jun 15, 2026 IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up Zacks · Jun 12, 2026 Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-31.0M$-44.0M$-49.0M$-55.0M$-45.0M
Investing Cash Flow$-76.0M$41.0M$7.0M$26.0M$-89.0M
Financing Cash Flow$-1.0M$0$0$1.0M$0
Net Cash Flow$38.0M$-2.0M$-13.0M$-23.0M$93.0M
Free Cash Flow$-31.0M$-45.0M$-49.0M$-55.0M$-45.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-27.39%
Quick Ratio32.45
Interest Coverage—
Return 1Y24.94%
Return 3Y-47.37%
Return 5Y—

Ownership

Insiders Held13.48%
Institutions Held47.72%
Institutions Float Held55.15%
Institutional HolderSharesReport Date
FMR, LLC9,697,9382026-03-31
Sanofi2,708,5592026-03-31
Vanguard Capital Management LLC2,288,3412026-03-31
Marshall Wace LLP1,996,5852026-03-31
Price (T.Rowe) Associates Inc1,829,1882026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
ASMB $26.68 +0.87% -51.53 $424.02M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%

About IMRX

IMRX is led by CEO Benjamin J. Zeskind, employs 54 people, headquartered in US, publicly traded since 2021.

IMRX stock trades at $4.24 with a market capitalization of $153.92M. The stock is valued at a price-to-earnings (P/E) ratio of -3.94, price-to-book of 0.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.29 and $10.08, and currently trades 57.9% below its 52-week high.

On profitability, IMRX generates a return on equity (ROE) of -25.69%, return on capital employed of -27.06%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides